ConductScience.org, home

Comparison · NCT04362111-5c2b5fdf

Anakinra Group vs Control Group: Patients Requiring Minimal Oxygen Support at Day 10

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

2 sourcestrial-comparisons-2026-03-23-0.1.0

Download JSON
Cite this record

ConductScience Library. Anakinra Group vs Control Group: Patients Requiring Minimal Oxygen Support at Day 10. Trial comparisons, record NCT04362111-5c2b5fdf. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT04362111-5c2b5fdf

On this page

Measures6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNote
Risk in group 10.5330.3010.752wilson
Risk in group 20.60.3570.802wilson
Risk difference, group 1 minus group 2-0.0667-0.3740.26newcombe hybrid score
Risk ratio, group 1 over group 20.8890.4741.67log
Odds ratio, group 1 over group 20.7620.1793.24log
Number needed to treat, for one fewer participant with the outcome on Anakinra Group than on Control Group15from the risk difference intervalthe interval includes no difference

Groups2

Group 2 names the comparator: control.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov code
Group 1Anakinra Group
The active treatment group will receive anakinra 100 mg subcutaneously every 6 hours for period of 10 days. For subjects meeting complete response criteria at 5 days, dosing will be decreased to 100 mg twice daily for the remaining 5 days.~Anakinra: The active treatment group will receive anakinra 100 mg subcutaneously every 6-12 hours for a period of 10 days
815OG000
Group 2Control Group
The control group will receive normal saline placebo subcutaneously every 6 hours for period of 10 days. For subjects meeting complete response criteria at 5 days, dosing will be decreased to twice daily for the remaining 5 days.~Normal saline: The control group will receive normal saline placebo subcutaneously every 6-12 hours for period of 10 days
915OG001

Outcome

Type
SECONDARY
Title
Patients Requiring Minimal Oxygen Support at Day 10
Description
Percentage of participants requiring no more than 2 L/min nasal canula oxygen to maintain oxygen saturation \>93% by Day 10
Time frame
0-10 days
Population

Source ClinicalTrials.gov

Trial

Title
Early Treatment of Cytokine Storm Syndrome in Covid-19
NCT number
NCT04362111
Phases
PHASE3
Conditions
Cytokine Storm, COVID-19
Interventions
Anakinra, Normal saline
Lead sponsor
University of Alabama at Birmingham
Results first posted
2023-08-24

Source ClinicalTrials.gov

Source

Release
trial-comparisons-2026-03-23-0.1.0
Release manifest SHA-256
f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
AACT copy
2026-03-23
Tables read
outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet

Source ClinicalTrials.gov

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

For software

Read this comparison from software.

The record is JSON. No key.

GET https://conductscience.org/api/comparisons/v1/NCT04362111-5c2b5fdf